Shots:

• Biomunex to receive up front- development- regulatory & sales milestones- equity investment along with royalties on sales of therapies
• Onward get the right to pursue development- manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program
• Biomunex is responsible for early preclinical development- while Onward will complete the IND-enabling studies- and will be responsible for GMP manufacture- clinical development- and commercialization

 ­ Ref: PRNewswire | Image: Onward